Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban

Research output: Contribution to journal › Editorial › Academic › peer-review

8 Citations (Scopus)

Access to Document

@article{9dded4ee100245d883cf7cfb2a8e848b,

title = "Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban",

author = "Levi, {M. [=Marcel M.]}",

year = "2012",

doi = "https://doi.org/10.1160/TH12-05-0330",

language = "English",

volume = "108",

pages = "201--202",

journal = "Thrombosis and haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "2",

}

TY - JOUR

T1 - Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban

AU - Levi, M. [=Marcel M.]

PY - 2012

Y1 - 2012

U2 - https://doi.org/10.1160/TH12-05-0330

DO - https://doi.org/10.1160/TH12-05-0330

M3 - Editorial

C2 - 22739774

SN - 0340-6245

VL - 108

SP - 201

EP - 202

JO - Thrombosis and haemostasis

JF - Thrombosis and haemostasis

IS - 2

ER -